Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Jade Biosciences, Inc.NASDAQ: JBIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$40.37M in Q1 FY2026
Q1 FY2026 net income was -$40.37M. Trailing-twelve-month net income was -$129.61M. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$82.64M (-35.1%) for the fiscal year ending Dec 2026, a slowdown from the +83.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$40.37M+26.4% QoQ
- Last fiscal yearDec 2025
- -$127.41M+83.0% YoY
- LTMMar 2026
- -$129.61M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +14.4% | — |
| 1 year | +83.0% | -35.1% | -118.1 pp |
| 3-year CAGR | +35.2% | -13.8% | -49.0 pp |
| 5-year CAGR | -10.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (127.41M) USD
- Year-over-year change
- -83.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (127.41M) | -83.0% |
| FY2024 | 2024-12-31 | (69.63M) | +7.8% |
| FY2023 | 2023-12-31 | (75.52M) | -46.6% |
| FY2022 | 2022-12-31 | (51.51M) | -124.3% |
| FY2021 | 2021-12-31 | (22.96M) | — |
Net Income vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 net income of $129.61M is the 5th largest of the 9 companies compared; the peer median is $117.27M.
- Over three fiscal years its annual growth of +35.2% compares with a peer median of +40.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $401.9M | +84.1% | +49.8% | — | |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $166.09M | +1.5% | — | — |
| LTM Mar 2026 | $156.4M | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $129.61M | — | +35.2% | — | |
| LTM Mar 2026 | $78.15M | +141.3% | -19.7% | — | |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M | +17.3% | +35.2% | — |
| LTM Mar 2026 | $28.32M | +28.8% | +40.9% | — | |
| Peer median (excluding JBIO) | $117.27M | +23.1% | +40.9% | 832.6% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (6.51M) | 7.76M | 9.8M | (11.17M) | (8.2M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 609K | 1.37M | (164K) | (2.17M) | 361K |
| Other Working Capital | (7.12M) | 6.39M | 9.96M | (9M) | (8.56M) |
| Other Non-Cash Items | 2.06M | 4.57M | 8.85M | 9.32M | 40.89M |
| Operating Cash Flow | (27.4M) | (39.12M) | (56.78M) | (71.2M) | (94.69M) |
| Capital Expenditures | (181K) | (195K) | (142K) | 0 | (196K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (113.25M) | (147.62M) | (123.98M) | (19.68M) | (261.19M) |
| Sales of Investments | 0 | 154.74M | 136M | 75.71M | 14.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (31K) |
| Investing Cash Flow | (113.43M) | 6.93M | 11.88M | 56.03M | (247.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.46M | 396K | 46M | 25.43M | 360.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 156K |
| Financing Cash Flow | 190.46M | 396K | 46M | 25.43M | 360.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (52.82M) |
| Net Change in Cash | 49.62M | (31.8M) | 1.09M | 10.26M | 54.69M |
| Free Cash Flow | (27.58M) | (39.32M) | (56.92M) | (71.2M) | (94.89M) |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.